Covered already by many folks, but this is a bit embarrassing...

Covered already by many folks, but this is a bit embarrassing for Katie Hudson.
- they have changed clinical practice, in this case providing a treatment in a highly unmet medical need space. A therapy for patients that never had one is the definition of changing clinical practice
- we have commercialisation sorted in the US, where it will be expensive for patients but payers have to cover (see first point)
- commercialisation ROW will come in good time
- distribution from our partnership with Acadia is all set.

I'm US-based, work in Biotech and have invested in NEU since 2011. I'm happy I did, but more importantly I'm happy patients have an option when they previously didn't. Working in this space there are very few feel-good stories in our industry. This is one of them.

Katie will figure that out in hindsight I'm sure and we all make mistakes! I thought I had around 2014-18, that's for sure.